{"title":"The Prognostic Value of Systemic Immune-Inflammation Index in Non-Small Cell Lung Cancer with ALK Rearrangement","authors":"B. Burak, S. Yucel","doi":"10.14744/ejmi.2020.41303","DOIUrl":"https://doi.org/10.14744/ejmi.2020.41303","url":null,"abstract":"DOI: 10.14744/ejmi.2020.41303 EJMI 2020;4(2):134–139","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130221990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Outcomes of Kaposi’s Sarcoma Treated with Systemic Chemotherapy","authors":"Abdilkerim Oyman","doi":"10.14744/ejmi.2020.96330","DOIUrl":"https://doi.org/10.14744/ejmi.2020.96330","url":null,"abstract":"DOI: 10.14744/ejmi.2020.96330 EJMI 2021;5(1):12–15","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121555638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Characteristics of Presentation and metabolic Risk Factors in Relation to Extent of Involvement in Infants with Nephrolithiasis","authors":"Kenan Yılmaz, Mustafa Erman Dorterler","doi":"10.14744/ejmi.2019.87741","DOIUrl":"https://doi.org/10.14744/ejmi.2019.87741","url":null,"abstract":"DOI: 10.14744/ejmi.2019.87741 EJMI 2020;4(1):78–85","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116701708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Effects of Isolated Oligohydramnios in Term Pregnancies on Labor, Delivery Mode, and Neonatal Outcomes","authors":"N. Yenigul, O. Aşıcıoğlu","doi":"10.14744/ejmi.2019.12005","DOIUrl":"https://doi.org/10.14744/ejmi.2019.12005","url":null,"abstract":"DOI: 10.14744/ejmi.2019.12005 EJMI 2019;3(1):59–64","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"29 2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127562603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.10130
G. Bulut
Objective: Ado-Trastuzumab Emtansine ( TDM1) has been used in the treatment of HER2 metastatic breast cancer after FDA approval as an antibody-drug conjugate. Some markers may be predictive for clinician in the management of this TDM1 therapy. There is a need for simple and cost-effective markers to show the treatment response. The primary aim of this study is to establish a correlation between progression free survival and pre-treatment hematological inflammatory parameters [absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR)] in advance breast cancer. Methods: Forty-one female patients with metastatic HER-2 positive breast cancer who received TDM-1 between 2016 and 2021 were evaluated retrospectively. NLR and PLR were calculated with the values of neutrophils, lymphocytes, and trombocytes in complete blood count at the time of diagnosis. The cut off values of NLR and PLR were determined using receiver operating characteristic (ROC) curve analysis. Overall survival (OS) and progression free survival (PFS) associated with prior treatment NLR, PLR, ALC were performed by Kaplan-Meier method. Results: Median age was 49.5 years years (26-76).Patients divided into 2 groups according to NLR cut-off and TLR cutoff values as NLR/TLR high and low groups. The cut-off values of NLR and TLR were 144.0, and 2.74, respectively. ALC divided into 2 groups. There was no significant difference in OS between NLR ,PLR,ALC (high/low) groups. (p=0.04, 0.15, 0.53 respectively). There was only significant difference in PFS (high/low) groups.(p=0.81, 0.99, 0.96 respectively). Conclusions: The predictive value of pre-treatment only NLR on the therapeutic potential in patients with metastatic breast cancer treated with TDM1.
{"title":"Predictive Value of Lymphocyte-Related Blood Parameters of before Ado-Trastuzumab Emtansin Treatment in Breast Cancer","authors":"G. Bulut","doi":"10.14744/ejmi.2022.10130","DOIUrl":"https://doi.org/10.14744/ejmi.2022.10130","url":null,"abstract":"Objective: Ado-Trastuzumab Emtansine ( TDM1) has been used in the treatment of HER2 metastatic breast cancer after FDA approval as an antibody-drug conjugate. Some markers may be predictive for clinician in the management of this TDM1 therapy. There is a need for simple and cost-effective markers to show the treatment response. The primary aim of this study is to establish a correlation between progression free survival and pre-treatment hematological inflammatory parameters [absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR)] in advance breast cancer. Methods: Forty-one female patients with metastatic HER-2 positive breast cancer who received TDM-1 between 2016 and 2021 were evaluated retrospectively. NLR and PLR were calculated with the values of neutrophils, lymphocytes, and trombocytes in complete blood count at the time of diagnosis. The cut off values of NLR and PLR were determined using receiver operating characteristic (ROC) curve analysis. Overall survival (OS) and progression free survival (PFS) associated with prior treatment NLR, PLR, ALC were performed by Kaplan-Meier method. Results: Median age was 49.5 years years (26-76).Patients divided into 2 groups according to NLR cut-off and TLR cutoff values as NLR/TLR high and low groups. The cut-off values of NLR and TLR were 144.0, and 2.74, respectively. ALC divided into 2 groups. There was no significant difference in OS between NLR ,PLR,ALC (high/low) groups. (p=0.04, 0.15, 0.53 respectively). There was only significant difference in PFS (high/low) groups.(p=0.81, 0.99, 0.96 respectively). Conclusions: The predictive value of pre-treatment only NLR on the therapeutic potential in patients with metastatic breast cancer treated with TDM1.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122509682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tuberculosis and Malignancy Coexistence with Cavitary Lesion in the Lung Radiologically","authors":"Gaye Celikkan","doi":"10.14744/EJMI.2019.29294","DOIUrl":"https://doi.org/10.14744/EJMI.2019.29294","url":null,"abstract":"DOI: 10.14744/ejmi.2019.29294 EJMI 2019;3(3):245-247","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127004582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.47497
O. Balta
Objectives: To determine the prevalence of enchondroma (EC) in adults, which was detected as an incidental finding in the lower extremity long bones on magnetic resonance imaging (MRI) and to detect imaging differences between EC and atypical chondroid tumor (ACT). Methods: A retrospective review of lower extremity MRI scans was performed in patients over 18 years of age. The location, size, and appearance of ECs and ACTs were established. The patients who were diagnosed with definitive EC and ACT after undergoing a biopsy were evaluated whether they had computed tomography (CT) examinations. Sagittal, coronal and axial reconstructions were performed in the patients with CT. Overall, minimum and maximum Hounsfield Units measurements were conducted in all 3 planes using region-of-interest (ROI) circles. Results: A total of 20,864 MR scans were reviewed. EC was detected in 2.2% and ACT in 0.08% of all MRIs including the lower extremity long bones. EC was observed to be most in the MR images taken for the knee (2.209%). EC was detected to be 1.6% in the proximal femur, 1.9% in the femur diaphysis, 1.8% in the distal femur, and 0.4% in the proximal tibia. Conclusion: The present study showed that tumors may be significant for ACT if their length is more than 4.5 cm, their width is greater than 2 cm, and they are growing more than 6 mm at follow-up. It was determined that the lower the CT attenuation measurements (Hounsfield Units), the higher the probability of having ACT. Abstract Cite This Article: Balta O, Altinayak H, Zengin EC, Eren MB, Demir O, Aytekin K. Incidental Enchondromas of the Lower Ex- tremity Long Bones and Atypical Chondroid Tumors Differentiation Based on Hounsfield Units. EJMI 2022;6(2):245–258.
目的:确定成人内软骨瘤(EC)的患病率，该疾病是在磁共振成像(MRI)上偶然发现的下肢长骨，并检测EC与非典型软骨样肿瘤(ACT)的影像学差异。方法:对18岁以上患者的下肢MRI扫描进行回顾性分析。确定ECs和ACTs的位置、大小和外观。活检后确诊为EC和ACT的患者评估是否进行了计算机断层扫描(CT)检查。CT对患者进行矢状面、冠状面和轴状面重建。总体而言，使用感兴趣区域(ROI)圆在所有3个平面上进行最小和最大Hounsfield单位测量。结果:共回顾了20,864张MR扫描。包括下肢长骨在内的所有mri中，EC检出率为2.2%，ACT检出率为0.08%。在膝关节的MR图像中，EC最多(2.209%)。EC在股骨近端为1.6%，股骨骨干为1.9%，股骨远端为1.8%，胫骨近端为0.4%。结论:本研究表明，如果肿瘤长度大于4.5 cm，宽度大于2 cm，随访时肿瘤生长大于6mm，则ACT可能具有显著意义。CT衰减测量值(霍斯菲尔德单位)越低，发生ACT的概率越高。Balta O, Altinayak H, Zengin EC, even MB, Demir O, Aytekin K.基于Hounsfield单位的下肢长骨偶发内生软骨瘤与非典型软骨样肿瘤的鉴别。EJMI 2022; 6(2): 245 - 258。
{"title":"Incidental Enchondromas Of The Lower Extremity Long Bones And Atypical Chondroid Tumors Differentiation Based On Hounsfield Units","authors":"O. Balta","doi":"10.14744/ejmi.2022.47497","DOIUrl":"https://doi.org/10.14744/ejmi.2022.47497","url":null,"abstract":"Objectives: To determine the prevalence of enchondroma (EC) in adults, which was detected as an incidental finding in the lower extremity long bones on magnetic resonance imaging (MRI) and to detect imaging differences between EC and atypical chondroid tumor (ACT). Methods: A retrospective review of lower extremity MRI scans was performed in patients over 18 years of age. The location, size, and appearance of ECs and ACTs were established. The patients who were diagnosed with definitive EC and ACT after undergoing a biopsy were evaluated whether they had computed tomography (CT) examinations. Sagittal, coronal and axial reconstructions were performed in the patients with CT. Overall, minimum and maximum Hounsfield Units measurements were conducted in all 3 planes using region-of-interest (ROI) circles. Results: A total of 20,864 MR scans were reviewed. EC was detected in 2.2% and ACT in 0.08% of all MRIs including the lower extremity long bones. EC was observed to be most in the MR images taken for the knee (2.209%). EC was detected to be 1.6% in the proximal femur, 1.9% in the femur diaphysis, 1.8% in the distal femur, and 0.4% in the proximal tibia. Conclusion: The present study showed that tumors may be significant for ACT if their length is more than 4.5 cm, their width is greater than 2 cm, and they are growing more than 6 mm at follow-up. It was determined that the lower the CT attenuation measurements (Hounsfield Units), the higher the probability of having ACT. Abstract Cite This Article: Balta O, Altinayak H, Zengin EC, Eren MB, Demir O, Aytekin K. Incidental Enchondromas of the Lower Ex- tremity Long Bones and Atypical Chondroid Tumors Differentiation Based on Hounsfield Units. EJMI 2022;6(2):245–258.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133695096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.21011
T. Koseci
Objectives: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are heterogeneous tumor groups, and they are rarely seen. Our study aims to analyze the clinicopathologic, demographic, and survival features of patients with GEP-NET. Methods: The data of 149 patients was collected retrospectively. Clinicopathologic, demographic, and survival features of patients with GEP-NET were investigated. Survival analysis was performed by using the Kaplan–Meier method and compared with the log-rank test. Univariate and multivariate analyses were performed to determine independent prognostic predictors of overall survival (OS). Results: Of 149 patients with GEP-NET, 65 patients (43.6%) were female and 84 patients (56.4%) were male. The most common, primary site of GEP-NET was stomach (40.3%). It was followed by pancreas (17.4%), small bowel/appendix (16.8%), colorectal (14%), and unknown primary (11.5%), respectively. The 3- and 5-year OS rate for the entire cohort were 69% and 60%, respectively. Median OS was not calculated, but the mean OS was 66.2 months. The factors significantly affecting the OS rate were age, grade, presence of metastasis at diagnosis, tumor diameter, and Ki-67 proliferation index in the univariate analysis. However, age was only meaningful in the multivariate analysis. Conclusion: Patients with GEP-NET under 50 age who have smaller tumor diameter, lower tumor grade, Ki-67 proliferation index, and absence of metastasis at the diagnosis have more prolonged survival. Abstract
{"title":"Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Evaluation of 149 Cases","authors":"T. Koseci","doi":"10.14744/ejmi.2022.21011","DOIUrl":"https://doi.org/10.14744/ejmi.2022.21011","url":null,"abstract":"Objectives: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are heterogeneous tumor groups, and they are rarely seen. Our study aims to analyze the clinicopathologic, demographic, and survival features of patients with GEP-NET. Methods: The data of 149 patients was collected retrospectively. Clinicopathologic, demographic, and survival features of patients with GEP-NET were investigated. Survival analysis was performed by using the Kaplan–Meier method and compared with the log-rank test. Univariate and multivariate analyses were performed to determine independent prognostic predictors of overall survival (OS). Results: Of 149 patients with GEP-NET, 65 patients (43.6%) were female and 84 patients (56.4%) were male. The most common, primary site of GEP-NET was stomach (40.3%). It was followed by pancreas (17.4%), small bowel/appendix (16.8%), colorectal (14%), and unknown primary (11.5%), respectively. The 3- and 5-year OS rate for the entire cohort were 69% and 60%, respectively. Median OS was not calculated, but the mean OS was 66.2 months. The factors significantly affecting the OS rate were age, grade, presence of metastasis at diagnosis, tumor diameter, and Ki-67 proliferation index in the univariate analysis. However, age was only meaningful in the multivariate analysis. Conclusion: Patients with GEP-NET under 50 age who have smaller tumor diameter, lower tumor grade, Ki-67 proliferation index, and absence of metastasis at the diagnosis have more prolonged survival. Abstract","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115352181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Third-line Treatment is Associated with Prolonged Survival in Patients with Extensive-Stage Small Cell Lung Cancer: A Single Center Experience","authors":"M. Karaağaç, M. Artaç","doi":"10.14744/ejmi.2020.47601","DOIUrl":"https://doi.org/10.14744/ejmi.2020.47601","url":null,"abstract":"DOI: 10.14744/ejmi.2020.47601 EJMI 2020;4(2):253–258","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"411 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123046672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2019.82298
Gregorio Viera Mármol, Carmen Cano Ochoa, Maria de los Llanos Pérez, Jorge Villena García, Reyna Vargas Lamas, Mar Altaba Rosas, Núria Adell Gómez, Jackie Law
{"title":"Safety, Efficacy and Patient Tolerance of the New 360º Cryoadipolysis Device for Multiple-area Fat Removal","authors":"Gregorio Viera Mármol, Carmen Cano Ochoa, Maria de los Llanos Pérez, Jorge Villena García, Reyna Vargas Lamas, Mar Altaba Rosas, Núria Adell Gómez, Jackie Law","doi":"10.14744/ejmi.2019.82298","DOIUrl":"https://doi.org/10.14744/ejmi.2019.82298","url":null,"abstract":"DOI: 10.14744/ejmi.2019.82298 EJMI 2020;4(1):41–50","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122703976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：